Kornimate/medical-research-clean huggingface dataset:
efficacy of stellate ganglion block in children with cerebral palsy and dysphagia

Conditions: Cerebral Palsy

Summary: the goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia of children with cerebral palsy? participants were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

cerebral palsy is a common non-progressive clinical condition characterized by motor disorders and abnormal postures, which significantly impact the quality of life of affected children. swallowing dysfunction is a common complication in children with cerebral palsy , affecting their daily eating and communication skills, and hindering their nutritional development and social interaction. stellate ganglion block has shown certain efficacy in improving swallowing function in children with cerebral palsy. however, there is limited research on the effects of stellate ganglion block treatment on swallowing dysfunction in children with cerebral palsy. therefore, this study aims to explore this topic and provide scientific evidence for its clinical application. the goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia of children with cerebral palsy? participants were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of cerebral palsy formulated by the 13th national conference on pediatric cerebral palsy rehabilitation; * age between 4 to 7 years; * diagnosed as dysphagia confirmed by dysphagia disorder survey or pediatric esophagoscopy; exclusion criteria: * with dysphagia caused by other diseases or factors; * with progressive neurological disease or degenerative neurological disease; * with severe heart disease, liver or kidney dysfunction, hematological disorders, or other acute and severe symptoms; * with abnormalities in the oral cavity, pharynx, esophagus, or other parts of the digestive tract; * with poor compliance.
an open-label, phase 2 study of acp-196 (acalabrutinib) in subjects with mantle cell lymphoma

Conditions: Mantle Cell Lymphoma (MCL)

Summary: the purpose of this study is to characterize the safety and efficacy profile of acp-196 (acalabrutinib) in subjects with relapsed or refractory mantle cell lymphoma (mcl).

this clinical trial is a phase 2, multicenter, (approximately 70 global centers), open-label study in subjects with histologically documented mcl, who have relapsed after, or were refractory to, ≥ 1 (but not \> 5) prior treatment regimens. subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (bid) in repeated 28-day cycles. treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. dose modification provisions are provided in the study protocol. all subjects will have hematology, chemistry, and urinalysis safety panels done at screening. once dosing commences (day 1), all subjects will be evaluated for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks in cycle 2, every 4 weeks in cycles 3 to 12, and every 24 weeks thereafter. pk/pd testing will be done in cycles 1 and 2. tumor assessments will be completed at 8- to 24-week intervals during the trial.

Eligibility criteria:
inclusion criteria: * men and women ≥ 18 years of age. * pathologically confirmed mcl, with documentation of monoclonal b cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin d1. * eastern cooperative oncology group (ecog) performance status of ≤ 2. * agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children. exclusion criteria: * a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acp-196 (acalabrutinib), or put the study outcomes at undue risk * significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the new york heart association functional classification, or corrected qt interval (qtc) \> 480 msec. * malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. * breast feeding or pregnant

Keywords: bruton tyrosine kinase inhibitor btk mantle cell lymphoma mcl acp-196 acalabrutinib ace-ly-004 calquence
the avastin vs visudyne for neovascular amd study

Conditions: Age-related Macular Degeneration

Summary: the object of the study is to compare the treatment effect of bevacizumab (avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (pdt) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the western world.

neovascular age-related macular degeneration (amd) is caused by an ingrowth of pathological vessels under the macula. experimental studies have demonstrated that vascular endothelial growth factor (vegf) is centrally involved in this process. current treatment options have up until now been limited to photodynamic therapy (pdt) where a photosensitizing agent in combination with laser is used to occlude the pathologic vessels. anti-vegf agents have recently become available making them a potentially attractive treatment alternative for neovascular amd. we will compare the effect intravitreally administered bevacizumab with conventional pdt in a prospective, randomized and controlled trial including 100 patients (50 patients receiving either treatment regimen). non-treated patients will receive either sham-injection or sham-pdt. the primary endpoint of the study is the amount of patients losing less than 15 letters on the etdrs visual acuity chart. the study will go on for 2 years with an interim report after 1 year.

Eligibility criteria:
inclusion criteria: * patients with subfoveal neovascular amd with either classic/predominantly classic or small occult lesions * visual acuity \>=0.1 exclusion criteria: * patients with subfoveal neovascular amd with minimally classic lesions or large occult lesions * subfoveal hemorrhage (\>1da) or fibrosis * patients previously treated for neovascular amd in the study eye

Keywords: neovascular age-related macular degeneration bevacizumab photodynamic therapy
digital patient journey solution for patients undergoing elective hip and knee arthroplasty dueto primary osteoarthritis

Conditions: Primary Elective Hip Arthroplasty (THA); Primary Elective Total Knee Arthroplasty (TKA)

Summary: this is an interventional study which aims at assessing the effects of a digital patient journey solution in patients undergoing elective hip and knee arthroplasty due to primary osteoarthritis.

traditionally, pre- and postoperative education has been provided face-to-face by paper-based methods for patients undergoing total hip arthroplasty (tha) and total knee arthroplasty (tka). digital patient journey solution has potential to enhance adherence to preoperative preparation and postoperative rehabilitation, and further improve patient experience, while reducing potential adverse events. the purpose of this study is to assess a digital patient journey solution developed for patients undergoing elective hip and knee arthroplasty. the digital solution aims to support patient's preparation to and recovery from a hip and knee arthroplasty through provision of timely information and support related to preoperative preparation and postoperative rehabilitation. the information on the application is aligned with the patient's individual needs and requirements, and contains exercises to be completed daily for the duration of the program.

Eligibility criteria:
inclusion criteria: * 18 years or older * undergoing primary elective total hip or knee arthroplasty * diagnosis of primary osteoarthritis of hip or knee (m16.0, m16.1, m17.0, m17.1) * ability to speak, read and understand finnish * access to a web-based device exclusion criteria: * undergoing a total hip or knee arthroplasty revision * a bilateral total hip or knee arthroplasty * total hip or knee arthroplasty following a rheumatoid arthritis * inability to walk with use of walking aids * unable to see or hear that impede the use of the digital patient journey solution
the evaluation of a new nasal mask for the treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of obstructive sleep apnea (osa) in the home environment.

the investigation is a prospective, non-randomized, non-blinded study. up to 45 osa participants who currently use a nasal, sub-nasal or pillows mask will be recruited. the study will involve a baseline (visit 1) data gathering with the participant's pap therapy and their usual mask. this will be followed by the participants being fitted with the trial nasal mask by a mask fitting expert for use in-home (visit 2). there will be a follow up phone call to gain feedback or address any issues after 3±1 days. the participant will then come in to return the mask (visit 3) and give feedback on their experience using the mask in home in the form of a structured interview during visit 3. if the participants prefer the trail nasal mask they will be asked if they would like to continue using the trial mask for a further six months in-home. there will be a follow up monthly phone call to gain feedback or address any issues during the extension. at the end of the six month extension period, the participants will return the trial nasal mask to the institution and give feedback on their experience using the mask in home in the form of a self-administered questionnaire. participants will revert to their usual masks thereafter. neither the participants nor the investigators will be blinded to the study.

Eligibility criteria:
inclusion criteria: * diagnosis of osa by physician * ≥ 22 years of age * ≥ 66 lbs * prescribed pap or bpap therapy for osa * existing nasal, sub-nasal and pillows mask users * fluent in written and spoken english exclusion criteria: * inability to give informed consent * pregnant or think they may be pregnant * pap intolerant * anatomical or physiological conditions that make pap inappropriate * ipap pressure of ≤25cmh20. * pap/bpap therapy device without data recording capabilities * using a pap/bpap therapy device for the delivery any medication with the exception of oxygen
deep learning algorithm for detecting obstructive coronary artery disease using fundus photographs

Conditions: Coronary Artery Disease; Artificial Heart Device User

Summary: artificial intelligence, trained through model learning, can quickly perform medical image recognition and is widely used in early disease screening and assisted diagnosis. with the continuous optimization of deep learning, the application of ai has helped to discover some previously unknown associations with other systemic diseases. artificial intelligence based on retinal fundus images can be used to detect anemia, hepatobiliary diseases, and chronic kidney disease, and to predict other systemic biomarkers. the above studies provide a theoretical basis for the application of artificial intelligence technology based on retinal fundus images to the diagnosis and prediction of cardiovascular diseases. at present, there is still a lack of accurate, rapid, and easy-to-use diagnostic and therapeutic tools for predictive modeling of coronary heart disease risk and early screening tools in china and the world. fundus image is gradually used as a tool for extensive screening of diseases due to its special connection with blood vessels throughout the body, as well as easy access, cheap and efficient. it is of great scientific and social significance to develop and validate a model for identification and prediction of coronary heart disease and its risk factors based on fundus images using ai deep learning algorithms, and to explore the value of ai fundus images in assisting coronary heart disease diagnosis and screening for a wide range of applications.


Eligibility criteria:
inclusion criteria: eligible participants were ≥ 18 years of age, with clinically suspected cad, and were scheduled for coronary angiography. exclusion criteria: the exclusion criteria were as follows: (i) prior percutaneous coronary intervention (pci); (ii) prior coronary artery bypass graft (cabg); (iii) other heart disease (e.g., congenital heart disease, valvular heart disease, or macrovascular disease); (iv) inability to have photographs taken; and (v) and a diagnosis of st-segment elevation myocardial infarction (stemi). prior to the coronary angiography procedure, all eligible patients provided informed consent to participate in the study and to have their photographs used for research purposes.
light emitting diode for thetreatment of genitourinary syndrome of menopause associated with breast cancer treatment

Conditions: Atrophy;Vaginal; Breast Cancer

Summary: breast cancer treatment may cause several side effects, some long lasting. adjuvant hormone therapy helps avoiding recurrence triggers vulvovaginal atrophy syndrome. this study evaluate a photodynamic treatment with light emitting diode to improve vaginal dryness and irritation, pruritus, pain or discomfort in intercourse.

the genitourinary menopause syndrome (mms) affects up to 70% of in treatment breast cancer patients. symptoms are due to a decrease in hormone levels or block to circulating hormones and induce functional changes in the vagina cutting in quality of life and impacting sexual function. this is a randomized, double blind trial in a sample of 74 individuals that will be performed at an specialized pelvic floor care center (caap) in brazil. will be included women age between 18 and 65 years, in adjuvant hormone therapy, with clinical signs and symptoms of vulvovaginal atrophy syndrome and cytologic evidence of atrophy, (ph \<5.0 and vaginal cytology with predominance of superficial cells). will be excluded from the study the patients in hormonal replacement for less than 6 months, diagnosis of vaginal infection, pregnant women, difficulty understanding the proposed instruments and patients with chronic neurological degenerative diseases. three 405 nm light emitting diode (led) sessions will be performed, with a seven days interval between them compared with sham procedure, and both groups will perform five sessions of kinesiotherapy sessions. maturation vaginal index will be checked before and after all treatment and self- administered questionnaires will be performed before each session with female sexual function index (fsfi) - female version (qs-f), female genital self-image scale - 7 (fgsis-7), international consultation on incontinence questionnaire - short form, (iciq-sf), functional assessment of cancer therapy - breast cancer (fact-b). at the end of treatment, the visual analog scale and likert scale will be used to measure the individual's satisfaction

Eligibility criteria:
inclusion criteria: * 18-65 anos * pathological proven breast cancer diagnosis * stage 0-iii by american joint committee on cancer (ajcc) and international union against cancer (uicc) of classification of malignant tumours, tnm (acronym for tumor-node-metastasis) 8ª edition * genitourinary syndrome of menopause confirmed through patient-reported symptoms and gynecological examination (of external structures, introitus, and vaginal mucosa) * vaginal ph \>5,0 exclusion criteria: * hormone replacement less than 6 months * diagnosis of vaginal infection * difficulty in understanding the proposed instruments * patients with chronic neurological degenerative diseases that preclude to be on position * metastatic disease * any vaginal photodynamic treatment less than 3 months

Keywords: vaginal atrophy breast cancer hormonal therapy photodynamic therapy light emitting diode
effects of korean red ginseng on semen parameters in male infertility patients: a randomized, placebo-controlled, double-blind clinical study

Conditions: Male Infertility

Summary: korean red ginseng (krg) has long been applied to various diseases as a health-promoting herbal medicine in korea. many clinical studies of ginseng have been performed to elucidate its therapeutic characteristics. krg has been shown to be effective in many diseases, such as cancers, hypertension, alzheimer's disease, diabetes, acquired immune deficiency syndrome, and sexual dysfunction. several studies have indicated effects of ginseng on improving spermatogenesis in animals. the major mechanisms behind these effects were speculated to be anti-oxidant and anti-aging effects, as well as modulation of the hypothalamus-pituitary-testis axis \[7 - 10\]. however, there have been no controlled human clinical trials to evaluate the effects of krg on spermatogenesis in patients with male infertility. only a small proportion of causes of male infertility are currently curable, including male hypogonadal disorders that can be cured by gonadotropic agents, and obstructive azoospermia that can be corrected by surgery. in addition, evidence-based medicine has revealed that most empirical treatments are ineffective. similarly, the efficacies of carnitine, anti-estrogens, kallikrein, vitamins c and e, and glutathione have not been confirmed. therefore, the investigators investigated the effects of krg on semen parameters in male infertility patients. this is the first placebo-controlled trial to evaluate the therapeutic effects of krg in male patients.


Eligibility criteria:
inclusion criteria: * patients should be males, 25 - 45 years of age, who had complained of infertility for at least 12 months, and had no history of surgical or medical treatments for infertility. * increased retrograde flow in the internal spermatic vein with venous diameter \> 3 mm during the valsalva maneuver on scrotal ultrasonography was used as an indicator of varicocele \[13\]. * varicocele was graded according to the criteria presented by lyon et al. \[14\]: \*grade i, palpable only with the valsalva maneuver * grade ii, palpable without the valsalva maneuver * grade iii, visible from a distance. exclusion criteria: * a history of vasectomy or obstructive azoospermia * chromosomal abnormalities * hypogonadism or pituitary abnormalities * anatomical abnormality of the genitals * significant hepatopathy (liver enzymes elevated 2 - 3-fold higher than the normal range) * renal insufficiency (serum creatinine level \> 2.5 mg/dl) * medical treatment for infertility during the past 4 weeks.

Keywords: effects of korean red ginseng on semen parameters in male infertility patients: a randomized, placebo-controlled, double-blind clinical study
same day discharge following pelvic reconstructive surgery

Conditions: Same Day Discharge; Pelvic Organ Prolapse; Total Vaginal Hysterectomy

Summary: this is a prospective cross-sectional study in which patients undergoing major pelvic reconstructive surgery with total vaginal hysterectomy will be recruited and enrolled. at approximately 2 weeks and 12 weeks postoperatively, enrolled patients will be asked to complete a survey detailing their experience with sdd, surgical recovery, and advice for prospective patients.


Eligibility criteria:
inclusion criteria: * total vaginal hysterectomy with or without bilateral salpingectomy/oophorectomy * apical repair with uterosacral ligament suspension or sacrospinous ligament fixation * they may also have any of the following concurrent procedures: anterior repair, posterior repair, enterocele repair, suburethral sling for incontinence * surgery by one of the fellowship trained urogynecologists at trihealth * english speaking exclusion criteria: * enrollment in the "diazepam research study" (protocol id:19-130) * concomitant procedure with another surgeon * chronic pain conditions that require daily use of narcotic pain medications (including but not limited to: chronic back or pelvic pain, interstitial cystitis, fibromyalgia) * concomitant anal sphincteroplasty, mesh removal or use of mesh for prolapse (excluding sling procedures)
cross-over broccoli sprouts trial

Conditions: Healthy

Summary: the study hypothesis tested is that broccoli sprouts are effective at altering the urinary levels of metabolites of the hepatocarcinogen aflatoxin b1 and of the air-borne pollutant phenanthrene in residents of qidong, prc, where exposures are unavoidable and high. the study will evaluate which of two formulations of broccoli sprouts beverage, glucoraphanin-rich or sulforaphane-rich, exhibits the best bioavailability and is most effective at modulating the biomarkers.


Eligibility criteria:
inclusion criteria: * adults aged 25-65 in good general health with no history of a chronic illness * normal liver function tests (alt, ast, bilirubin) * normal renal function tests (creatinine, bun, urinalysis) * serum alpha-fetoprotein negative exclusion criteria: * personal history of cancer, except for non-melanoma skin cancer * use of prescribed medications * hepatomegaly by clinical exam * unwillingness to avoid cruciferous vegetable consumption for the duration of the study * for women, a positive pregnancy test.

Keywords: sulforaphane pharmacokinetics
micro-surgical treatment of gummy smile

Conditions: Pain, Postoperative

Summary: compare pain response following microsurgical conventional flap approach using piezosurgery versus flapless approach for esthetic crown lengthening in management of patients with short clinical crowns in the upper anterior region.

the conventional approach: anesthesia will be given followed by bone sounding using william graduated periodontal probe and measuring the pocket depth (using magnification loupes and microsurgical blades) * marking the bleeding points * an internal bevel incision is made followed afterwards by a sulcular incision. * the gingival collar is eliminated. * elevation of the flap is proceeded to allow access for osteoplasty using piezo surgery and an apical position of the bone 2-3mm beyond cej. * mattress suture (6.0) is made the intervention approach: surgery is done the same as in the conventional approach but without opening a flap, gaining access via a tunneling instrument and piezo tips for osteoplasty

Eligibility criteria:
inclusion criteria: 1. patients with healthy systemic condition. 2. adult patients ˃ 18 years old. 3. the presence of the six upper anterior teeth. 4. patients who have short clinical crowns due to altered passive eruption classified as type i subclass b (coslet, vanarsdall and weisgold, 1977). 5. absence of sites with attachment loss and probing depth (pd) \>3 mm. 6. keratinized gingiva of at least 2mm width (pontoriero and carnevale, 2001). 7. compliance with good oral hygiene. 8. patients accepts 6-months follow-up period (cooperative patients). 9. patients provides an informed consent. exclusion criteria: 1. presence of prosthetic crowns 2. extensive restorations 3. extensive incisal edge attrition. 4. smokers ˃ 10 cigarettes / day 5. pregnant females